IRMO, SC -- (MARKET WIRE) -- May 18, 2007 -- Blood Diagnostics, Inc. (BDI), one of the leading distributors of recombinant and plasma-derived pharmaceutical products, today announced immediate availability of HepaGam B, the first intravenous hepatitis B immune globulin approved by the FDA. Because the products can be administered intravenously, the HepaGam B enables healthcare providers to treat HBsAg-postive liver transplant patients prophylactically to prevent hepatitis B recurrence following transplantation.
